Grifols is a global, Spanish-based biotech company that is a favorite for many European investors, despite the fact that the company does not pay a dividend. It's one of the more well-known Spanish ...
Seeking Alpha: Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
It's time for an update on the Medical company Grifols, S.A. (GRFS). It's been about 4 months since I last updated on the business, with that update being specific to an event where Brookfield Asset ...
MADRID, June 7 (Reuters) - Spain's Grifols has agreed to buy U.S.-based Talecris Biotherapeutics , which makes plasma-based protein medicines, for $3.4 billion in a bold move to expand its business in ...
Health Canada said on April 1 that it added new terms and conditions to the licences of all 16 Grifols clinics in the country “due to recurring, systemic deficiencies across several sites.” Joanna ...
Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a ...
Seeking Alpha: Grifols: Solid Q3 Execution, But Cash Conversion And 2026 Risks Keep Us Neutral
Grifols: Solid Q3 Execution, But Cash Conversion And 2026 Risks Keep Us Neutral
Hello, everyone. My name is Danny Segarra, and myself as the Head of Investor Relations and Sustained and Vice President, Grifols. Welcome to our review of the company's Business Results for the First ...
Spanish drugmaker Grifols SA is facing restrictions on its Canadian licence to collect blood products following the deaths of two patients who made plasma donations in the country. Health Canada, ...